Pfizer joins Beam Therapeutics to develop rare disease therapies

Beam will receive $300 million in upfront payment and lead research activities till three new therapy targets are selected for development from outside the firm's existing programs, the companies said on Monday.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3zJ9dmN
via IFTTT